Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Noninvasive Prenatal Testing Detects Most Chromosomal Abnormalities

By LabMedica International staff writers
Posted on 20 Feb 2014
Noninvasive prenatal testing detected 83.2% of chromosomal abnormalities normally picked up by invasive diagnostic testing strategies, such as chorionic villus sampling (CVS) or amniocentesis.

Noninvasive prenatal testing (NIPT) using cell free DNA provides accurate screening for the common trisomies, including trisomy 13, Patau syndrome, trisomy 18, Edwards syndrome, and trisomy 21, Down syndrome.

Specialist in maternal-fetal medicine at the University of California, San Francisco (CA, USA) carried out a study on rare chromosome abnormalities detected by current prenatal screening compared to expected performance using noninvasive prenatal testing. More...
There were 68,990 of 1,324,607 women who tested positive for trisomy 18 or 21 when they underwent prenatal screening between March 2009 and December 2012.

Invasive diagnostic testing with CVS or amniocentesis was performed on 26,059 women who tested positive, and 2,993 were found to have abnormal results. Of those chromosomal abnormalities, 2,489 (83.2%) were abnormalities that would be detectable with NIPT, while 16.8% were less common aneuploidies that would not be detected. The scientists found that more of the abnormal results were detectable in the women over the age of 40, who are at higher risk for trisomy 13, 18, or 21. Conversely, fewer of the abnormalities in younger women would be detected by NIPT, as the risk for common trisomies is lower in this group, while the rare aneuploidies are not typically associated with maternal age.

Mary Norton, MD, one of the study’s authors, said, “While noninvasive prenatal testing with cell free DNA presents some real advantages in accuracy of screening for Down syndrome, as with everything there is a trade-off. Traditional aneuploidy screening with serum and ultrasound markers has higher false positive rates, but in these false positive cases are some fetuses with significant abnormalities that would not be found with NIPT.”

Dr. Norton added, “In prenatal genetic testing, patient preferences are really the most important driver. With this test, the patient makes a tradeoff between NIPT, which is noninvasive and detects most, but not all chromosome abnormalities, and is somewhat better in older women, and amniocentesis or CVS, which detect more chromosome abnormalities, 8% to 25% more, depending on age, but with a small risk of miscarriage due to the procedure. For an older woman, detecting 83% with the noninvasive test may be good enough, while for a 25-year-old, failing to detect 25%, which may include rare aneuploidies not usually associated with age, may be of concern.” The study was presented on February 6, 2014, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, held in New Orleans (LA, USA).

Related Links:

University of California, San Francisco



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.